Search results

3 items
  1. UN High-Level Segment on Drugs, March 2014

    28 February 2014
    Article

    On March 13-14, 2014, UN member states will gather in Vienna, Austria, for a High Level Segment of the annual UN Commission on Narcotic Drugs (CND). The purpose of this meeting is to review the progress made, and the challenges encountered, since the 2009 Political Declaration and Plan of Action on the World Drug Problem. The main focus of the High Level Segment will be the negotiation of a Joint Ministerial Statement, which will set the scene for the 2016 UN General Assembly Special Session on Drugs (UNGASS), as well as recording member states’ views of progress.

  2. UNODC’s shifting position on drug policy: Progress and challenges

    • International Drug Policy Consortium (IDPC)
    31 January 2014
    Policy issue

    In March 2014, country delegations will gather at the United Nations Commission on Narcotic Drugs (CND) to review progress and challenges in international drug control since the agreement of a Political Declaration on drugs in 2009. Given that the Political Declaration aims to “eliminate or reduce significantly” the use, supply and demand of controlled drugs by 2019, this meeting represents an important opportunity for honest evaluation and an acknowledgement that these targets are not being achieved. With a United Nations General Assembly Special Session (UNGASS) on drugs just two years away, this is an important time for international drug control policy.

  3. UNODC Executive Director releases "contributions" ahead of CND High-Level Segment on drugs

    19 January 2014
    Article

    Ahead of the High-Level Segment on the world drug problem to take place on 13th and 14th January 2014, the UNODC Executive Director, Yuri Fedotov, has released his "contributions" to the debate. This 19-page document is, in parts, refreshingly honest about the “unequal” progress that has been made since 2009 (with reductions in supply or demand for some drugs in some places being offset by increases elsewhere), the setbacks and new challenges, and the fact that “the overall magnitude of drug demand has not substantially changed at the global level”.